Latest News & Features
article
Learning to determine the value technological advance has contributed requires a great degree of sophistication, Randall Rader said in a session on protecting biotechnology innovations in the US and Latin America at the 2014 BIO International Convention in San Diego, California, yesterday (Tuesday). 25 June 2014
article
The whole international patent community has been reasonably good at developing new patent laws but hopeless at compliance, said Francis Gurry, director general of the World Intellectual Property Organization. 25 June 2014
Americas
The American public's access to new and effective medicines could be at risk as a result of the US Supreme Court's decisions in the Prometheus and Myriad cases, and the resulting guidance for examiners from the USPTO, according to a report presented to the 2014 BIO International Convention in San Diego today. 25 June 2014
Americas
The Indian Patent Office has rejected a patent application for an anti-cancer drug for the second time, paving the way for generic versions to potentially enter the market. 24 June 2014
Americas
Teva has reached a settlement in its patent battle with two pharmaceutical companies, ending all litigation over its ProAir HFA (albuterol sulfate) inhalation aerosol. 23 June 2014
Biotechnology
Europe’s highest court has said that products used by agrochemical companies to help maintain plants can be given extended patent protection. 20 June 2014
Americas
Acting against infringers can involve the pharmaceutical regulatory framework and civil law as well as following the more usual pathways, says José R. Trigueros. 20 June 2014
Americas
Amended rules for food and drink packaging seek to ensure that people can easily identify the high calorific content of some of these products, as Daniel Sanchez and Victor Ramirez report. 20 June 2014
Americas
The rate of development in the biotech sector means revisions to the patent guidelines are more needed than ever, says Marisa Moura Momoli. 20 June 2014
Americas
The patent regulatory framework in Mexico needs to evolve if the investment in, and marketing of, promising biotechnology drug products is to succeed, says Hector E. Chagoya. 20 June 2014